Clinical trial
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer
NCT00194727 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00194727 |
|---|---|
| Title | Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer |
| Official title | Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer: A Phase II Trial With Molecular Correlates |
| Lead sponsor | University of Washington, Other |
| Collaborators | Hoffmann-La Roche Industry Pfizer |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasm |
| Intervention type | Drug |
| Interventions | Vinorelbine, Capecitabine |
| Enrollment | 40 |
| Start date | May 1, 2002 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: